+

WO2004001423A1 - Molecules module rapporteurs presentant une activite du canal ionique - Google Patents

Molecules module rapporteurs presentant une activite du canal ionique Download PDF

Info

Publication number
WO2004001423A1
WO2004001423A1 PCT/GB2003/002715 GB0302715W WO2004001423A1 WO 2004001423 A1 WO2004001423 A1 WO 2004001423A1 GB 0302715 W GB0302715 W GB 0302715W WO 2004001423 A1 WO2004001423 A1 WO 2004001423A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
ion channel
reporter module
molecule according
reporter
Prior art date
Application number
PCT/GB2003/002715
Other languages
English (en)
Inventor
John Colyer
Original Assignee
University Of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Leeds filed Critical University Of Leeds
Priority to AU2003277986A priority Critical patent/AU2003277986A1/en
Priority to EP03740756A priority patent/EP1554585A1/fr
Publication of WO2004001423A1 publication Critical patent/WO2004001423A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection

Definitions

  • the present invention relates to ion channel reporter module molecules, methods of producing such module molecules and uses therefore especially in detecting interactions between proteins such as heterodimer or homodimer formation and/or mapping interaction circuits of membrane proteins and/or for assessing therapeutic efficacy of agents on, for example, hormone or receptor binding. Further uses of the reporter module molecules include detecting protein interactions in healthy and disease states and as biosensors.
  • transient interaction between proteins is a key component of most biological processes and is central to the passage of information in signal transduction cascades.
  • receptors oligomerise in the presence of a ligand and initiate a signalling cascade; in other examples adapter molecules, effector molecules or courier molecules interface briefly with the ligand bound receptors.
  • Transient interactions between proteins are used throughout biological systems as a means, for example, of inhibiting enzyme function, re-tuning enzyme specificity and as a means of transferring information across physical barriers.
  • the assembly and disassembly of competent protein complexes is dynamic and the frequency of interaction is regulated so as to control the biological process in question.
  • Information transfer across a membrane is an important aspect of biology, which invariably involves the transient interaction between membrane proteins. Errors in this information transfer process can cause disease states (e.g.diabetes mellitis).
  • the code used by hormones to transfer information into the cell is complex. Signals are heterogeneous with respect to their -intensity, duration, frequency and spatial distribution. Each of these qualities conveys only part of a message and is subsequently decoded by the cell and used to fine-tune the response to the original stimulus.
  • Our understanding of the components of a signal and its decoding is inextricably linked with the development of the enabling technology. The understanding of such processes, is best exemplified in the field of Ca 2+ -signalling. In this specific example, cell permeable Ca 2+ -sensitive dyes were developed which were able to measure intracellular Ca 2+ ion concentrations in living cells.
  • Proteimprotein interactions are important for another reason in that the sequencing of entire genomes from a variety of organisms needs to be translated for a greater understanding of the molecular basis of biological "events”. This translation requires an understanding of how proteins interact with one another, which proteins they each interact with, and how these interactions change with respect to time and circumstance and different cell environments. The mapping of such protein interaction circuits, particularly those involving proteins in the plasma membrane, we believe will be facilitated by the present invention which will be detailed hereinafter.
  • the ion channel, gramicidin acts as the signal device to mark antibody: antigen interaction, in this way specific interactions of cell membrane bound proteins may be studied. It is also known to tether/attach such membranes to a solid inorganic surface such as gold to form electrode-membrane combinations for use as biosensors (WO97/01092). However, the membrane itself and the technique employing them have limited application in cell biology since gramicidin cannot be expressed in most cells and tethering the membrane to a gold substrate is not applicable to production and use in a live cell context.
  • a reporter module molecule comprising a first target protein directly fused to or linked via a linker to a first ion channel fragment and a second target protein directly fused to or linked via a further linker to second ion channel fragment, so that when the target proteins interact the two said ion channels fragments are in close proximity and spontaneously reconstitute to form an active ion channel.
  • ion channel activity is the "output" device providing the means for detecting a biological event or interaction.
  • the ion channel activity may be measured directly by means of electrical conductivity or it may be measured by, for example and without limitation, fluorescence which occurs as a result of or consequence of ion channel activity.
  • Reference herein to a reporter module molecule is intended to include a reporter group which utilises ion channel activity or a consequence of ion channel activity as the means for detecting or reporting a biological event or protein interaction.
  • a reporter module molecule comprising a first target protein directly fused to or linked via a linker to an ion channel and a second target protein directly fused to or linked via a further linker to an ion channel inhibitor, so that when the target proteins interact the ion channel is inhibited.
  • Each target protein is fused to a component of a channel.
  • two targets could be fused to components of a channel which are able to reconstitute into a functional channel.
  • each target could be fused to an ion channel fragment.
  • a plurality of targets could each be fused to channel portions of different proportions.
  • the target proteins are associated with a linker, they are fused to the linkers.
  • the linker comprises a hydrophilic, protease resistant, flexible structure of length at least one and up to 100 residues, preferably it comprises in the region of at least one to 20 residues.
  • the ion channel is a peptic ion channels, such as the M2 protein of influenza virus, mellitin, a NB protein of influenza B, a SH protein of paramyxovirus SV5, a vpu protein of HIV- 1 or mutant forms or fragments thereof.
  • a peptic ion channels such as the M2 protein of influenza virus, mellitin, a NB protein of influenza B, a SH protein of paramyxovirus SV5, a vpu protein of HIV- 1 or mutant forms or fragments thereof.
  • the ion channel reporter (ICR) module molecule of the present invention is constructed using simple, naturally occurring, peptide cation channels such as and, by way of example only, the influenza M2 protem transmembrane domain. Preferably, two copies of this transmembrane domain are linked via an additional transmembrane domain to form an ion channel fragment.
  • ICR ion channel reporter
  • two such channel fragments are brought into close proximity by the interaction of at least one upstream or downstream receptor protein.
  • Synthetic receptors and ligands based on coiled-coil structures will ideally be linked to the aforementioned channel fragment modules.
  • the peptide ion channel module is selected so that it possesses characteristics required by the reporter technology of the present invention.
  • the ion channel is capable of conducting monovalent or divalent ions, and preferably it possesses a low open probability when expressed as free peptides but an enhanced open probability when such peptides are brought close to each other in space by the interaction of domains fused to each peptide.
  • the transmembrane domain of influenza M2 protein is an attractive candidate for the ion channel module of the present invention.
  • a peptide of preferably, about 25 amino acids in length, based on the wild type sequence of the transmembrane domain of influenza M2 protein is known to form a proton (and Na ) channel in black lipid membranes (Duff & Ashley, 1992).
  • the spontaneous association of monomeric peptide units to a functional tetramer forms these proton channels. This self-assembly occurs with low frequency and a short lifetime ( ⁇ 20ms) which is able to create an ion channel of low open probability and low unit conductance.
  • mutant forms of the M2 protein transmembrane domain may be even better candidates for the ion channel module of the present invention.
  • a mutant lacking 4 residues from the transmembrane domain displays enhanced ion conductance (when expressed in oocytes, ⁇ 40-fold cf. Wild type M2) and is operative at neutral pH (Pinto et al., 1992), whereas the wild type sequence is active at acidic pH.
  • this mutant form is the ion channel conductor.
  • a further advantage of the present invention is based on using all L-residue ion channels as the output device.
  • Preferably ion channels are, in one embodiment all L- residues. All cells will be able to express the reporter group giving it universal applicability in cell biology.
  • the ion channel fragment is provided with a linker it is fused to the linker.
  • At least one ion channel fragment is further associated with a green fluorescent protein (GFP) reporter.
  • GFP green fluorescent protein
  • At least one channel ion fragment may be further associated with an epitope so that its presence may be detected immunologically.
  • proteimprotein interaction by, for example, measuring electrophysiology parameter or by using ion specific dyes.
  • the first and/or second target protein is a receptor molecule, such as and without limitation, a human growth hormone.
  • the first protein may comprise Nef (from HTV-1) and the second protein a host CD4 receptor, the interaction therebetween being a transient event, which permits evasion of the immune response by the HIV virus.
  • the proteins may be substrates for protein kinases where their association is influenced by the state of phosphorylation of at least one partner. Accordingly the present invention allows measurement of kinase and/or phosphatase activity as an indicator of proteimprotein interaction.
  • the first protein is a G-protein coupled receptor and the second protein is a G-protein.
  • the second protein is a G-protein.
  • GPCR G-protein coupled receptors
  • the reporter technology can be used to study this aspect of GPCR signal transduction. It can also be used to identify compounds that modify the transduction of signals through this pathway.
  • the first and/or second target proteins of interest may be each or singly membrane bound.
  • the first and/or second target proteins of interest may each or singly are soluble proteins.
  • the reporter module molecule may be modified so that it preferably carries a phosphoryl group and/or another suitable group that influences its association with a binding partner.
  • a coiled coil poypeptide can be engineered to contain a phosphorylation (or other modification) site, which influences association with a partner in a phosphorylation (or other modification) status dependent manner.
  • phosphorylation status of the reporter molecule which is indicative of kinase and/or phosphatase activity, can be measured at a location close to a membrane.
  • the reporter module molecule may also be modified so that it is fused to an intermediate template, preferably the template is provided with appropriate side chains to facilitate attachment to the ion channel fragment.
  • the technique may be used in live cells, both in vitro and in vivo. It is envisaged that discrimination between heterodimer formation and homodimer formation will assist in mapping interactions in such cells.
  • the coiled-coil polypeptides having an addition site for a phosphate, ubiquitin, glycosyl or ADP-ribosyl moiety are used in assays for monitoring or modulating protein modification.
  • the reporter module molecule preferably comprises a coiled-coil and at least one engineered site for the addition of at least one of the following: a phosphate, ubiquitin, glycosyl or ADP-ribosyl moiety, where the polypeptide binds to at least one binding partner in at least one of the following manners: phosphorylation, ubiquitination-, glycosylation- or ADP-ribosylation-dependent manner.
  • ICR module molecule of the present invention in the study of heterodimerisation and/or homodimerisation of growth hormone receptors in order to define temporal and spatial qualities of signal transduction.
  • a method of detecting proteimprotein interactions, interference with receptor binding, change in healthy and disease states and/or screening a ligand library comprising contacting a first protein linked to a first ion channel fragment under investigation with a second protein linked to a second ion channel fragment and measuring ion channel activity.
  • the reporter module molecule of the present invention is versatile in that activity of the ion channel may be used to measure either when there is activity of the ion channel or when there is inhibition of normal activity, hi this way the turning on or off of the ion channel activity in the presence of environmental conditions and or foreign agents maybe assessed.
  • kits for determining the proteimprotein interaction of a biological system in real time comprising the reporter module molecule as hereinbefore described and optionally including a coiled -coil comprising an engineered site for the addition of a phosphate, ubiquitin, glycosyl or ADP-ribosyl moiety, where the polypeptide binds to at least one binding partner in a phosphorylation-, ubiquitination-, glycosylation- or ADP- ribosylation-dependent manner, and packaging materials;
  • a method to monitor the activity of proteimprotein interactions by monitoring the addition of at least one of: phosphate, ubiquitin, glycosyl or ADP-ribosyl moiety to at least one polypeptide.
  • a method to monitor the activity of proteimprotein interactions comprising monitoring the removal of at least one of: phosphate, ubiquitin, glycosyl or ADP-ribosyl moiety from at least one polypeptide.
  • the products and methods of the present invention can be used for monitoring and/or modulating protein :protein interaction/modification which may be involved in repair, replication, recombination and packaging, secretion and chromosome condensation, cell cycle control, cell growth, inflammation, signal transduction, immune response and malignant transformation. They can also be used in the screening of candidate bioactive agents (e.g.
  • drugs for efficacy or side effects, whereby the ability of such an agent to modulate the activity of a protein ⁇ rotein interaction may be indicative a a therapeutic effect or propensity toward provoking unintended side-effects to a therapeutic or other regimen in which that agent might be used.
  • a therapeutic agent identified by the screening method of the present invention in the preparation of a medicament for the treatment of hormone related and/or protein related and/or irnmunity conditions/diseases and/or 1 to control parasites or pests.
  • the technology of the present invention permits the imaging of receptor protein activation, which by analogy with the Ca 2+ -signalling field, will enable the decoding of signal transduction messages in new and greater depth. Furthermore, the technology of the present invention will be able to identify interacting partners for all plasma membrane proteins, and in this format will facilitate understanding of proteomic information through the construction of protein interaction circuits.
  • array formats of this technology of the present invention will provide high throughput platforms for the identification of new drug molecules (which inhibit or promote protein interaction) and novel platforms for the construction of, for example, biosensors.
  • the reporter module molecule of the present invention may be engineered so as to be a biosensor.
  • the reporter module molecule may be attached to a chip or another appropriate substrate.
  • the reporter module molecule as hereinbefore described incorporated into a membrane.
  • the reporter module molecule as hereinbefore described incorporated into a cell.
  • the reporter technology of the present invention is based on the transient reconstitution of an active ion channel during the period of association of the two proteins under study. Ion channels have immense activity as they harness the electrochemical gradient of their permeant ion species which provides significant signal amplification for the reporter technology.
  • M2 protein of influenza virus mellitin
  • the protein of influenza B SH protein of paramyxovirus SV5, vpu protein of HIV-1
  • M2 protein or mutant or any forms thereof.
  • the ion channel fragment modules will meet infrequently, and thus channel activity will be absent or low.
  • the ion channel modules will collide with increased frequency and reconstitute an active channel protein.
  • FIG. 1 schematically represents membrane protein interactions
  • Figure 2 represents an ion channel fragment module
  • Figure 3 represents conversion of a non-functional ion channel fragment module to a functional ion channel reporter molecule
  • Figure 4 illustrates the receptor and ion channel domains of the HGG-M2A peptide
  • Figure 5A represents monomeric peptides
  • 5B represents Ni co-ordinated peptide dimers
  • 5C represents an active ion channel tetramer
  • Figure 6 shows HGG-M2A activity at -120 mV in the absence of nickel and
  • Figure 7 shows HGG-M2A activity at -120 mV in the presence of nickel.
  • membrane protein interaction is detected by the transient reconstitution of an ion channel during the period of interaction of the proteins of interest ( Figure 1).
  • the target proteins are expressed as fusion proteins, in which the reporter module comprises a protein domain equivalent to one fragment of a simple ion channel.
  • the reporter module comprises a protein domain equivalent to one fragment of a simple ion channel.
  • the receptordigand interaction we have developed is a coiled-coil receptor interacting with a coiled-coil ligand.
  • Lee et al. (1996) described a coiled-coil "template sequence" (based on the leucine zipper sequence of GCN4) and which served as a template for the docking of two shorter coiled-coil peptides.
  • template sequence based on the leucine zipper sequence of GCN4
  • One peptide docked to the N-terminal region of the template sequence and the other peptide docked to the C-terminal fragment of the template.
  • We used the template peptide concept as our "ligand", which is able to cross-link (non-covalently) two short coiled- coil "receptors”. These receptors can each be fused to the ion channel fragment modules.
  • a coiled-coil sequence other than GCN4 used by Lee et al., 1996) so that we can adjust the affinity of interaction (length and sequence can be altered in design to fine tune binding affinity), and to ensure that we avoid unwanted hybridisation (with endogenous GCN4) if used in yeast.
  • the ligand proposed is a coiled-coil peptide of 42 residues (6 heptads) which is able to hybridise to the receptors on each copy of the ion channel fragment which will each comprise 3 heptad long coiled-coil proteins (Figure 2a). Using the design principles outlined in O'Shea et al.
  • the receptor coiled-coils will not dimerise with one another, but will each bind with sub-micromolar (readily tunable by altering sequence and length of peptide) affinity to the ligand.
  • Design of the ion channel fragment module :
  • the ion channel fragment module comprises two copies of the peptide channel (M2 transmembrane domain, or a mutant form thereof), joined in series by a linker sequence which traverses the membrane forming an anti-parallel three helix structure ( Figure 2b).
  • the sequence of the linker transmembrane helix can either be modelled on known monomeric transmembrane proteins with the correct topology (e.g. endopeptidase 24.11, Koehne et al., 1998; glycophorin C, Cartron et al., 1993) or it could be a poly-leucine ⁇ -helix which also forms a monomeric tranmembrane domain (Zhou et al. 2000, Choma et al, 2000).
  • the inclusion of positively charged cytoplasmic loops will aid insertion of the protein in the membrane with the desired topology.
  • Other non-helical transmembrane ion channel sequences could be used.
  • the ligand can be synthesised chemically (42-mer peptide), as can the receptor- fragment channel proteins (-120 residues).
  • the protein may be expressed in bacteria from artificial genes created from synthetic oligonucleotides.
  • the protein purified by affinity chromatography, can be reconstituted into lipid vesicles using standard techniques and the ion channel activity analysed in black lipid membranes. We predict that the frequency of spontaneous ion channel reconstitution would be higher in this format than was seen with monomeric channel peptides.
  • the receptor-fragment channel constructs may be expressed in mammalian cells.
  • the reporter group can be further modified in two ways.
  • a leader sequence and topology control cues may be added to the construct to ensure plasma membrane insertion of the protein and desired orientation of the protein (extracellular N-terminus).
  • the construct can incorporate a fluorescent protein at the C- terminus to facilitate the detection of the location of this protein in the cell (GreenFP, RedFP Clontech).
  • the transient expression of this construct in HEK 293, CHO or cos cells are performed using the fluorescence of the C-terminal fluorescent protein to review protein expression
  • Imaging of cells expressing the GFP-reporter are used to identify whether the reporter protein has been correctly targeted to the plasma membrane. Once plasma membrane targeting of the reporter protein has been confirmed, the ion channel activity of the cells can be evaluated using the whole cell patch clamp technique.
  • the basal activity of the reporter channel can be defined by comparison of transfected and untransfected cells, and then the ligand dependent stimulation of channel activity can be determined in both cell types. Large increases in reporter channel activity may be expected in the presence of ligand.
  • the reporter activity can also be observed using fluorescent dyes for intracellular pH and intracellular Na+.
  • fluorescence technology is more widely available than patch clamp technology; secondly, the fluorescence technology is readily adapted to high throughput methods formats of experimental conduct and thirdly that spatial heterogeneity of a signal can be detected using the optical techniques.
  • Fluorescent dyes are commercially available for both of these ions (BCECF, SBFI, Molecular Probes) and these may be employed to establish the most sensitive fluorimetric end-point for this reporter activity.
  • the fluorescent readout can be examined by fluorirnetry and also imaged by confocal microscopy to examine the temporal and spatial resolution of the reporter technology.
  • C and D the interaction between two receptor domains (C and D) is controlled by the phosphorylation status of C and D.
  • C and D can have identical sequence (below) and a homodimer is formed whilst the coiled coil is dephosphorylated, whereas dimer formation is prevented when at least one of the partners is phosphorylated.
  • the sequence of C (and D) in this example is: RM QLEDQVl ⁇ RLRRKSYHLENEVAALKKLVGERAAK (SEQ ID NO:l)
  • Interacting protein C is phosphorylated and upon interaction with a second protein D the phosphoryl group is lost. Proteins C and D are fused to templates 5 each being provided with further side chain linkages to the ion channel fragments 1 and 2.
  • Growth hormone is a polypeptide hormone of 191 residues which activates a plasma membrane receptor by promoting the dimerisation of the receptor (analogous to the synthetic ligand:receptor, above).
  • This homo-dimerisation of the receptor lends itself to analysis using the reporter technology of the present invention.
  • the signals for targeting and orientating the construct in the plasma membrane are all contained within the GHR protein.
  • the ion channel fragment module requires the opposite topology to that described in previous examples.
  • GHR reporter group in mammalian cells (HEK 293, CHO or cos7, as above) can confirm the plasma membrane location of the reporter protein (C- terminal GFP tag or immuno logical epitope).
  • the ligand concentration dependence of receptor activation (bell shaped; Wells, 1994), the temporal and spatial response to ligand presentation will be described.
  • Nef from HTV-l
  • the interaction of Nef (from HTV-l) with the host CD4 receptor is a transient event, which permits evasion of the immune response by the HTV virus.
  • the background literature indicates that there is no tendency for homo- oligomer formation of either CD4 or Nef, and thus the reporter technology in its current state of development can be used in this particular case of heterodimer observation.
  • the reporter technology of the present invention can be refined further to allow investigators to discriminate between homo-dimer and hetero-dimer interactions. Building this discriminating power is a yet further advantage of the present invention.
  • the ability to map interaction circuits for a particular membrane protein of interest is a yet further advantage of the present invention.
  • the association of a protein with a second copy of itself (homodimer) can trigger the ion channel reconstitution and thus prevent the identification of interactions with other partners.
  • the residues involved in stabilising the oligomeric structure of the homo-pentameric protein phospholamban have been identified by site directed mutagenesis (Simmerman et al., 1996). These all reside within the transmembrane domain. The size, shape and chemical property of the residues on the interface between sub-units control the oligomeric state of membrane proteins (Simmerman et al., 1996, Zhou et al., 2000, Choma et al., 2000), thus providing an opportunity to design reporters capable of discriminating between homo- and hetero- interactions.
  • the ion channel modules can be designed such that reconstitution of identical channels is prohibited, but reconstituted of non-identical channels is permitted. Walshaw & Woolfson (U.
  • the peptide sequence NH 2 -H G G S S D P L V V A A S I I G I L A L IL W I L D R L - COO " (SEQ ID NO:2) is divided into receptor and ion channel domains as shown in Figure 4.
  • the ion channel sequence is a modified form of influenza virus M2 protein transmembrane domain in which a histidine residue has been altered to alanine (A in SEQ ID 2). Wild type sequence displays ion channel activity at acidic pH, this mutant sequence displays ion channel activity at neutral pH.
  • the receptor module (HGG) is a metal binding feature.
  • the tri-peptide HGG has been shown to bind to Ni 2+ and Cu 2+ in a 2:1 complex between pH 6.5 and 7.5 (Zhang Y., Akilesh S. & Wilcox D.E. (2000). Inorg. Chem. 39: 3057-3064). Therefore, detection of the metal ions will be through an increased occurrence of channel formation, which will result in increased channel activity.
  • the postulated mode of action is depicted in Figures 5A-C.
  • the process, with regard to Figure 5A shows as a first step that monomeric peptides (M) will move freely in a bilayer and will transiently interact to give an active ion channel (tetrameric).
  • a black lipid membrane (also known as a planar lipid membrane/bilayer) was formed by 'painting' (Mueller P., Rudin D.O., Tien H.T. & Wescott W.C. (1963). J. Phys. Chem. 67: 534 - 537) a lipid solution across a 200 ⁇ m aperture in a polycarbonate cup.
  • the lipid phophatidylethanolamine also known as cephalin
  • a stable bilayer had a capacitance between 80 - 200 pF, and a current of +/- 0.5 A at an applied potential of +/- 60 V.
  • HGG-M2A is a reporter module molecule with a potential to allow the study of heterodimerisation and/or homodimerisation of proteimprotein interactions so as to define temporal and spatial qualities of signal transduction and may find further utility as a screening agent for identifying suitable therapeutics which alter ion channel activity.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une molécule module rapporteur comprenant une première protéine cible directement fusionnée à un premier fragment de canal ionique ou liée à ce premier fragment de canal ionique par un lieur et une seconde protéine cible directement fusionnée à un second fragment de canal ionique ou liée à ce second fragment de canal ionique par un autre lieur, de sorte que lorsque les protéines cibles interagissent, les deux fragments de canal ionique se trouvent à proximité immédiate l'un de l'autre et se reconstituent spontanément pour former un canal ionique actif. L'invention concerne également des applications de la molécule module rapporteur, notamment l'étude de l'hétérodimérisation et/ou de l'homodimérisation des interactions protéine-protéine ainsi que des méthodes d'identification de partenaires de liaison d'une protéine cible d'une banque d'ADNc ou d'une banque de ligands.
PCT/GB2003/002715 2002-06-25 2003-06-25 Molecules module rapporteurs presentant une activite du canal ionique WO2004001423A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003277986A AU2003277986A1 (en) 2002-06-25 2003-06-25 Reporter module molecules having active ion channel activity
EP03740756A EP1554585A1 (fr) 2002-06-25 2003-06-25 Molecules module rapporteurs presentant une activite du canal ionique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214553.0 2002-06-25
GB0214553A GB0214553D0 (en) 2002-06-25 2002-06-25 Reporter module molecules having active ion channel activity

Publications (1)

Publication Number Publication Date
WO2004001423A1 true WO2004001423A1 (fr) 2003-12-31

Family

ID=9939183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002715 WO2004001423A1 (fr) 2002-06-25 2003-06-25 Molecules module rapporteurs presentant une activite du canal ionique

Country Status (4)

Country Link
EP (1) EP1554585A1 (fr)
AU (1) AU2003277986A1 (fr)
GB (1) GB0214553D0 (fr)
WO (1) WO2004001423A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001159A1 (fr) * 1987-07-27 1989-02-09 Commonwealth Scientific And Industrial Research Or Membranes receptrices
WO1990008783A1 (fr) * 1989-01-27 1990-08-09 Australian Membrane And Biotechnology Research Institute Membranes receptrices et selection par ionophores
WO1995008637A1 (fr) * 1993-09-21 1995-03-30 Washington State University Research Foundation Dosage immunologique comportant un recepteur de canal d'ions conjugue a un ligand immobilise dans un film de lipides
WO1997020203A1 (fr) * 1995-11-28 1997-06-05 Thomas Schalkhammer Nouvelles membranes et nouveaux capteurs d'adn/arn a membrane
WO1998034120A1 (fr) * 1997-01-31 1998-08-06 Universite De Montreal Analyses par complementation de fragments proteiques pour detecter des interactions biomoleculaires
WO1999011774A1 (fr) * 1997-08-30 1999-03-11 Fluorescience Limited Polypeptides a structure bispiralee comportant un site d'addition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001159A1 (fr) * 1987-07-27 1989-02-09 Commonwealth Scientific And Industrial Research Or Membranes receptrices
WO1990008783A1 (fr) * 1989-01-27 1990-08-09 Australian Membrane And Biotechnology Research Institute Membranes receptrices et selection par ionophores
WO1995008637A1 (fr) * 1993-09-21 1995-03-30 Washington State University Research Foundation Dosage immunologique comportant un recepteur de canal d'ions conjugue a un ligand immobilise dans un film de lipides
WO1997020203A1 (fr) * 1995-11-28 1997-06-05 Thomas Schalkhammer Nouvelles membranes et nouveaux capteurs d'adn/arn a membrane
WO1998034120A1 (fr) * 1997-01-31 1998-08-06 Universite De Montreal Analyses par complementation de fragments proteiques pour detecter des interactions biomoleculaires
WO1999011774A1 (fr) * 1997-08-30 1999-03-11 Fluorescience Limited Polypeptides a structure bispiralee comportant un site d'addition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORNELL B A ET AL: "A biosensor that uses ion-channel switches", NATURE, MACMILLAN MAGAZINES, US, vol. 387, no. 6633, 5 June 1997 (1997-06-05), pages 580 - 583, XP002140886, ISSN: 0028-0836 *
HAHNENBERGER KAREN M ET AL: "Use of microphysiometry for analysis of heterologous ion channels expressed in yeast", NATURE BIOTECHNOLOGY, vol. 14, no. 7, 1996, pages 880 - 883, XP001155679, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
EP1554585A1 (fr) 2005-07-20
GB0214553D0 (en) 2002-08-07
AU2003277986A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
Chen et al. SNARE-mediated membrane fusion
Olivier et al. Antibody-mimetic peptoid nanosheets for molecular recognition
Gallivan et al. Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins
Jackson et al. Fusion pores and fusion machines in Ca2+-triggered exocytosis
CN103228669B (zh) 基于荧光共振能量转移的原理的单分子型fret生物传感器接头
CA2224086C (fr) Composition de banques combinatoires a limitation conformationnelle et procedes d'utilisation
JP2005513999A (ja) オリゴヌクレオチド識別子
US20140209475A1 (en) Nanohair structure and an application therefor
JPWO2009096304A1 (ja) 嗅覚受容体を模倣した感応膜を有するケミカルセンサ
Chen et al. A highly sensitive fluorescent Akt biosensor reveals lysosome-selective regulation of lipid second messengers and kinase activity
Juhaniewicz et al. Electron transport mediated by peptides immobilized on surfaces
Alfinito et al. Proteotronics: development of protein-based electronics
US7282347B2 (en) Method for extracting quantitative information relating to interactions between cellular components
Rockett et al. Cluster-Enhanced Nanopore Sensing of Ovarian Cancer Marker Peptides in Urine
Kirsch et al. Membrane protein binding interactions studied in live cells via diethylpyrocarbonate covalent labeling mass spectrometry
Ma et al. Label-Free Mapping of Multivalent Binding Pathways with Ligand–Receptor-Anchored Nanopores
Blake et al. Chemically reactive derivatives of gramicidin A for developing ion channel-based nanoprobes
McPherson et al. Peptide motifs: building the clathrin machinery
CA2384170C (fr) Sonde de visualisation de gmp cyclique et procede de detection et de quantification de gmp cyclique faisant intervenir cette sonde
Fahrenkrog et al. The vertebrate nuclear pore complex: from structure to function
EP1554585A1 (fr) Molecules module rapporteurs presentant une activite du canal ionique
DE102005060920A1 (de) Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung
CN104781667A (zh) 荧光融合多肽、包含所述多肽的生物感应器及其用途
Szöllősi et al. Mapping of membrane structures by energy transfer measurements
Jeon Surface Functionalization of Bioanalytical Applications: Virus-decorated Gold Microshells and Modified Synaptic Cell Adhesion Molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003740756

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003740756

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003740756

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载